COUR NanoParticle (CNP) Technology Induces Antigen Specific Tolerance, Halting the Progression of Type 1 Diabetes in Spontaneous NOD Model
CHICAGO, Aug. 1, 2022 /PRNewswire/ — COUR Pharmaceuticals, a clinical stage biotechnology company developing novel immune-modifying nanoparticles (COUR NanoParticles…